The synthesis and biological activity of N-heteroaryl substituted benzene sulphonamides (3a–h) were successful. Simple condensation reaction of benzene sulphonyl chloride (1) with substituted heteroaromatic compounds (2a–h) under dry pyridine and acetone gave the target molecules (3a–h) in good to excellent yield. The compounds were characterized using FTIR, 1HNMR, and 13CNMR. The compounds were screened for antibacterial activity against E. coli, Salmonella typhi, P. aeruginosa, B. cereus, K. pneumonia, and Sarcina？？lutea and antifungal activity against C. albicans and A. niger. The results of the antimicrobial activity showed improved biological activity against some tested organisms. 1. Introduction A large number of sulphonamide derivatives have ultimately been reported to show substantial protease inhibitory properties [1]. Sulphonamides are synthetic antimicrobial agents which act as competitive inhibitors of the enzyme dihydropteroate synthetase (DHPS) [2]. The basic sulphonamide group, SO2NH, occurs in various biological active compounds widely used as antimicrobial drugs, antithyroid agents, antitumor, antibiotics, and carbonic anhydrase inhibitors [3, 4]. Clinically, sulphonamides are used to treat several urinary tract infections and gastrointestinal infections [5]. Aromatic or heteroaromatic sulphonamides that are used as antitumor agent act by inhibiting carbonic anhydrase. Structurally, sulphonamides are similar to p-aminobenzoic acid (PABA) which is a cofactor needed by bacteria for the synthesis of folic acid and therefore could compete for incorporation. Sulphonamide antibiotics are used as veterinary medicines to treat infections in livestock herds [6, 7]. Additionally, sulphonamides are extremely useful pharmaceutical compounds because they exhibit a wide range of biological activities such as anticancer, anti-inflammatory, and antiviral activity [8–12]. The sulphonylation of amines with sulphonyl chlorides in the presence of a base is still being used as the method of choice because of high efficiency and simplicity of the reaction [13]. However, this approach is limited by the formation of undesired disulphonamides with primary amines and by the need of harsh reaction conditions for less nucleophilic amines such as anilines [14]. Additionally, side reactions take place in the presence of a base. Sulphonamides have been used as protecting groups of OH or NH functionalities for easy removal under mild conditions [15, 16]. Resistance to sulphonamides by bacteria is most likely a result of a compensatory increase in the biosynthesis of
References
[1]
A. Casini, A. Scozzafava, and C. T. Supuran, “Sulfonamide derivatives with protease inhibitory action as anticancer, anti-inflammatory and antiviral agents,” Expert Opinion on Therapeutic Patents, vol. 12, no. 9, pp. 1307–1327, 2002.
[2]
Sulphanomide—Medicine, “The Free Encyclopedia,” 2009, http://en.wikipedia.org/wiki/su/fonamide.
[3]
C. T. Supuran, A. Scozzafava, L. Menabuoni, F. Mincione, F. Briganti, and G. Mincione, “Carbonic anhydrase inhibitors. Part 71: synthesis and ocular pharmacology of a new class of water-soluble, topically effective intraocular pressure lowering sulfonamides incorporating picolinoyl moieties,” European Journal of Pharmaceutical Sciences, vol. 8, no. 4, pp. 317–328, 1999.
[4]
M. Remko and C.-W. von der Lieth, “Theoretical study of gas-phase acidity, pKa, lipophilicity, and solubility of some biologically active sulfonamides,” Bioorganic & Medicinal Chemistry, vol. 12, no. 20, pp. 5395–5403, 2004.
[5]
A. K. Gaded, C. S. Mahajanshetti, A. Nimbalkar, and A. Raichurkar, “Synthesis and antibacterial activity of some 5-guanylhydrazone/thiocyanato-6-arylimidazo[2,1-b]-1,3,4-thiadiazole-2-sulfon amide derivatives,” European Journal of Medicinal Chemistry, vol. 35, no. 9, pp. 853–857, 2003.
[6]
N. S. El-Sayed, E. R. El-Bendary, S. M. El-Ashry, and M. M. El-Kerdawy, “Synthesis and antitumor activity of new sulfonamide derivatives of thiadiazolo[3,2-a]pyrimidines,” European Journal of Medicinal Chemistry, vol. 46, no. 9, pp. 3714–3720, 2011.
[7]
M. J. Garcia-Galan, M. S. Diaz-Cruz, and D. Bercelo, “Identification and determination of metabolites and degradation products of sulfonamide antibiotics,” Trends in Analytical Chemistry, vol. 27, no. 11, pp. 1008–1022, 2008.
[8]
C. T. Supuran, A. Casini, and A. Scozzafava, “Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents,” Medicinal Research Reviews, vol. 23, no. 5, pp. 535–558, 2003.
[9]
A. Scozzafava, T. Owa, A. Mastrolorenzo, and C. T. Supuran, “Anticancer and antiviral sulfonamides,” Current Medicinal Chemistry, vol. 10, no. 11, pp. 925–953, 2003.
[10]
W. G. Harter, H. Albrect, K. Brady et al., “The design and synthesis of sulfonamides as caspase-1 inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 3, pp. 809–812, 2004.
[11]
N. S. Reddy, M. R. Mallireddigari, S. Cosenza et al., “Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 15, pp. 4093–4097, 2004.
[12]
B. R. Stranix, J. F. Lavallee, G. Sevigny et al., “Lysine sulfonamides as novel HIV-protease inhibitors: Nε-Acyl aromatic α-amino acids,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 13, pp. 3459–3462, 2006.
[13]
K. K. Anderson and D. N. Jones, vol. 3, Pergamon Press, Oxford, UK, 1979.
[14]
A. Yasuhara, M. Kameda, and T. Sakamoto, “Selective monodesulfonylation of N, N-disulfonylarylamines with tetrabutylammonium fluoride,” Chemical and Pharmaceutical Bulletin, vol. 47, no. 6, pp. 809–812, 1999.
[15]
J. F. O'Connell and H. Rapoport, “1-(Benzenesulfonyl)- and 1-(p-toluenesulfonyl)-3-methylimidazolium triflates: efficient reagents for the preparation of arylsulfonamides and arylsulfonates,” Journal of Organic Chemistry, vol. 57, no. 17, pp. 4775–4777, 1992.
[16]
S. Chandrasekhar and S. Mohapatra, “Neighbouring group assisted sulfonamide cleavage of sharpless aminols under acetonation conditions,” Tetrahedron Letters, vol. 39, no. 7, pp. 695–698, 1998.
[17]
R. Gleckman, S. Alvarez, and D. W. Joubert, “Drug therapy reviews: trimethoprim-sulfamethoxazole,” The American Journal of Hospital Pharmacy, vol. 36, no. 7, pp. 893–906, 1979.
[18]
S. R. Bushby and G. H. Hitchings, “Trimethoprim, a sulphonamide potentiator,” British Journal of Pharmacology, vol. 33, no. 1, pp. 72–90, 1968.
[19]
G. Thomas, Medicinal Chemistry, John Wiley and Sons, 2nd edition, 2007.
[20]
N. Ozbek, H. Katircioglu, N. Karacan, and T. Baykal, “Synthesis, characterization and antimicrobial activity of new aliphatic sulfonamide,” Bioorganic and Medicinal Chemistry, vol. 1, no. 15, pp. 5105–5109, 2007.
[21]
C. O. Vincent, Pharmaceutical Microbiology: Principles of the Pharmaceutical Applications of Antimicrobial Agents, El 'Demak Publishers, Enugu, Nigeria, 2005.
[22]
R. Soleymani, N. Niakan, S. Tayeb, and S. Hakimi, “Synthesis of novel aryl quinoxaline derivatives by new catalytic methods,” Oriental Journal of Chemistry, vol. 28, no. 2, pp. 687–701, 2012.
[23]
S. K. Anandan, “1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia,” Bioorganic & Medicinal Chemistry Letters, vol. 21, no. 3, pp. 983–988, 2011.
[24]
L. Tietze and F. FMajor, “Synthesis of new water-soluble DNA-binding subunits for analogues of the cytotoxic antibiotic CC-1065 and their prodrugs,” European Journal of Organic Chemistry, vol. 10, pp. 2314–2321, 2006.
[25]
G. P. Claxton, L. Allen, and J. M. Grisar, “For peptide synthesis, synthesis of 2,3,4,5-tetrahydropyridine,” Organic Syntheses. Collective Volume, vol. 6, p. 968, 1988.
[26]
K. Shin-Ya, J.-S. Kim, K. Furihata, Y. Hayakawa, and H. Seto, “Structure of kaitocephalin, A novel glutamate receptor antagonist produced by eupenicillium shearii,” Tetrahedron Letters, vol. 38, no. 40, pp. 7079–7082, 1997.
